4 recruiting, 1 active not recruiting, 1 not yet recruiting. 6 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Recruiting 4, Active not recruiting 1, Not yet recruiting 1 |
| Phase 1 | 1 | Not yet recruiting 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow Odronextamab: new trials by email Literature Review of Odronextamab trials Research Report on Odronextamab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| REGN9220 in Combination With Odronextamab in Adult Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphomas (BCNHLs) REGN9220, Odronextamab - Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 1 / Phase 2 | Not yet recruiting | Regeneron Pharmaceuticals | 36 | 2026-12-07 | 2026-10-21 |
| Odronextamab in Low Tumor Volume Advanced FL Odronextamab - Follicular Lymphoma, Lymphoma | Phase 2 | Recruiting | Gottfried von Keudell, MD PhD | 35 | 2025-09-08 | 2026-03-13 |
| Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T Odronextamab, Biospecimen Collection, Bone Marrow Aspiration - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 2 | Recruiting | University of Washington | 27 | 2025-09-04 | 2026-08-28 |
| Odronextamab for the Treatment of Relapsed and Refractory Diffuse Large B-cell Lymphoma Before and After Chimeric Antigen Receptor T-cell Therapy Chimeric Antigen Receptor T-Cell Therapy, Odronextamab - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma | Phase 2 | Recruiting | University of California, Davis | 34 | 2025-08-07 | 2026-07-08 |
| A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma Odronextamab, Loncastuximab tesirine, Rituximab - B-cell Non Hodgkin Lymphoma | Phase 2 / Phase 3 | Recruiting | University of Birmingham | 210 | 2024-05-02 | 2026-02-20 |
| A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer Therapies Odronextamab - B-cell Non-Hodgkin Lymphoma (B-NHL) | Phase 2 | Active not recruiting | Regeneron Pharmaceuticals | 515 | 2019-11-13 | 2026-07-31 |
Lymphoma, Large B-Cell, Diffuse (4) · Lymphoma, B-Cell (2) · Lymphoma, Follicular (2) · Lymphoma (1) · Lymphoma, B-Cell, Marginal Zone (1) · Lymphoma, Mantle-Cell (1)
Regeneron Pharmaceuticals (2) · Gottfried von Keudell, MD PhD (1) · University of Birmingham (1) · University of California, Davis (1) · University of Washington (1)
United States (4) · Australia (2) · United Kingdom (2) · Austria (1) · Belgium (1) · Canada (1) · China (1) · France (1) · Germany (1) · Italy (1) · Japan (1) · Netherlands (1) · New Zealand (1) · Poland (1) · Singapore (1)
Amos Burke (1) · Gottfried Von Keudell, MD, PhD (1) · Joseph M Tuscano, MD (1) · Mengyang Di, MD, PhD (1)
PMID 40097657, PMID 40472301, PMID 40902079, PMID 41766170
2017 (1), 2025 (1), P30CA093373 (1)